Seattle-based Oncothyreon (NASDAQ: ONTY) has named Scott D. Myers its new president and CEO. Myers most recently ran Aerocrine, a diagnostics company that Circassia Pharmaceuticals bought for $214 million last year. He also had stints at UCB and Johnson & Johnson before that. Christopher Henney had been serving as Oncothyreon’s interim CEO after Robert Kirkman retired in January. Myers will take over for Henney on April 4.